The evaluation of hyperferritinemia: An updated strategy based on advances in detecting genetic abnormalities

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1185-1194

  Aguilar Martinez, Patricia ^a   Schved, Jean François ^b   Brissot, Pierre ^b  

^a HÔPITAL SAINT ELOI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; FERRITIN; GENE PRODUCT; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; IRON; PROTEIN HJV; PROTEIN TFR2; TRANSFERRIN; UNCLASSIFIED DRUG; HFE2 PROTEIN, HUMAN; MEMBRANE PROTEIN;

AUTOSOMAL RECESSIVE DISORDER; BIOCHEMISTRY; DIFFERENTIAL DIAGNOSIS; DOMINANT INHERITANCE; EVALUATION; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; HEMOCHROMATOSIS; HEREDITARY HYPERFERRITINEMIA; HFE GENE; HJV GENE; HUMAN; HYPERFERRITINEMIA; IRON METABOLISM; IRON OVERLOAD; NEUROLOGIC DISEASE; ONSET AGE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SYMPTOMATOLOGY; TFR2 GENE; TRANSFERRIN BLOOD LEVEL; ADULT; BLOOD; CHROMOSOME ABERRATION; CLASSIFICATION; GENETICS; IRON METABOLISM DISORDER; MUTATION;

ADULT; CHROMOSOME ABERRATIONS; FERRITINS; HEMOCHROMATOSIS; HUMANS; IRON METABOLISM DISORDERS; IRON OVERLOAD; MEMBRANE PROTEINS; MUTATION;

EID: 19144362107     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40998.x     Document Type: Review

References (87)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
2. Prchal JT, Pospisilova D, Mims MP, et al. Identification of the first human mutation of DMT1 (Nramp2) in a patient with microcytic anemia and iron overload. Blood 2003;102(Suppl 1):754a.
3. Pietrangelo A. Hereditary hemochromatosis - A new look to an old disease. N Engl J Med 2004;350:2383-97.
4. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004;363:357-62.
5. Castiella A, Alustiza JM, Artetxe J. Hereditary hemochromatosis. N Engl J Med 2004;351:1263-4.
6. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
7. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24-9.
8. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002;36:673-8.
9. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115:929-36.
10. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
11. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:251-2.
12. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-51.
13. Distante S, Berg JP, Lande K, et al. High prevalence of the hemochromatosis-associated Cys282TyrHFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999;34:529-34.
14. de Villiers JN, Hillerman R, de Joug G, et al. High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary haemochromatosis in South Africa. S Afr Med J 1999;89:279-82.
15. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93:111-23.
16. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-7.
17. Brissot P, Troadec MB, Loréal O. Intestinal absorption of iron in HFE-1 haemochromatosis: Local or systemic process? J Hepatol 2004;40:702-9.
18. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
19. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
20. Rhodes DA, Raha-Chowdhury R, Cox TM, et al. Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. J Med Gene 1997;34:761-4.
21. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Review. Blood 2003;101:3347-50.
22. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
23. McCune CA, Al-Jader LN, May A, et al. Hereditary haemochromatosis: Only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002;111:538-43.
24. Deugnier Y, Jouanolle AM, Chaperon J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: A study of 9396 French people. Br J Haematol 2002;118:1170-8.
25. Rochette J, Cadet E, Thein SL, et al. Penetrance of the HFE C282Y homozygote in North of France: Implications for public health, (abstract). Blood 2002(Suppl 1):834.
26. Brissot P, Troadec MB, Loréal O. The clinical relevance of new insights in iron transport and metabolism. Curr Hematol Rep 2004;3:107-15.
27. Aguilar-Martinez P, Bismuth M, Picot MC, et al. Variable phenotypic presentation of iron overload in H63D homozygotes: Are genetic modifiers the cause? Gut 2001;48:836-42.
28. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-16.
29. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241-7.
30. Jacolot S, Le Gac G, Scotet V, et al. HAMP as a modifier gene that increase phenotypic expression of the HFE C282Y homozygous genotype. Blood 2003 Dec 11 (Epub ahead of print).
31. Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-805.
32. Aguilar Martinez P, Biron C, Blanc F, et al. Compound heterozygotes for hemochromatosis gene mutations: May they help to understand the pathophysiology of the disease? Blood Cells Mol Dis 1997;23:269-76.
33. Rossi E, Olynyk JK, Cullen DJ, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000;46: 162-6.
34. Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002;122:646-51.
35. Tomatsu S, Orii KO, Fleming RE, et al. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc Natl Acad Sci U S A 2003;100:15788-93.
36. Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-3.
37. Dereure O, Aguilar-Martinez P, Bessis D, et al. HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: A prospective study of 36 cases from southern France. Br J Dermatol 2001;144:533-9.
38. Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999;23(274):20826-32.
39. Aguilar-Martinez P, Esculie-Coste C, Bismuth M, et al. Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis. Blood Cells Mol Dis 2001;27:290-3.
40. Barton EH, West PA, Rivers CA, et al. Transferrin receptor-2 (TFR2) mutation Y250X in Alabama Caucasian and African American subjects with and without primary iron overload. Blood Cells Mol Dis 2001;27:279-84.
41. Lee PL, Halloran C, West C, et al. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol Dis 2001;27:285-9.
42. Girelli D, Bozzini C, Roetto A, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002;122:1295-302.
43. Biasiotto G, Belloli S, Ruggeri G, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003;49:1981-8.
44. Mattman A, Huntsman D, Lockitch G, et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: Identification of a novel TfR2 mutation. Blood 2002;1(100):1075-7.
45. Hattori A, Wakusawa S, Hayashi H, et al. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003;26:154-6.
46. Piperno A, Roetto A, Mariani R, et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004;89:359-60.
47. Frazer DM, Anderson GJ. The orchestration of body iron intake: How and where do enterocytes receive their cues? Blood Cells Mol Dis 2003;30:288-97.
48. Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983;65:149-54.
49. Camaschella C, Roetto A, De Gobbi M. Juvenile hemochromatosis. Semin Hematol 2002;39:242-8.
50. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
51. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2.
52. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-9.
53. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;98:8780-5.
54. Roetto A, Daraio F, Porporato P, et al. Screening hepcidin for mutations in juvenile hemochromatosis: Identification of a new mutation. Blood 2003 Nov 20 (Epub ahead of print).
55. Matthes T, Aguilar Martinez P, Bosman-Pizzi L, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5′ UTR of the hepcidin gene. Blood 2004; first edition paper, prepublished online June 15.
56. Delatycki M, Allen K, Gow P, et al. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clin Genet 2004;65:378-383.
57. Majore S, Binni F, Pennese A, et al. HAMP gene mutation C.208T > C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. Hum Mutat 2004;23:400.
58. Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003;34:97-101.
59. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.
60. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
61. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003;361:669-73.
62. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-601.
63. Lanzara C, Roetto A, Daraio F, et al. The spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004; first edition paper, prepublished online Feb 24.
64. Lee PL, Beutler E, Rao SV, et al. Genetic abnormalities and juvenile hemochromatosis: Mutations of the HJV gene encoding hemojuvelin. Blood 2004; first edition paper, pre-published online Feb 24.
65. Beaumont C, Leneuve P, Devaux I, et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995;11:444-6.
66. Girelli D, Corrocher R, Bisceglia L, et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: A mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). Blood 1995;86:4050-3.
67. Njajou OT, Vaessen N, Joosse M. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-4.
68. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-23.
69. Fang F, Naylor SL, Lum JB, et al. Characterization, mapping, and expression of the human ceruloplasmin gene. Proc Natl Acad Sci U S A 1986;83:3257-61.
70. Hetet G, Devaux I, Soufir N, et al. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003;1(102):1904-10.
71. Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001;69:191-7.
72. Ferreira C, Santambrogio P, Martin ME, et al. Ferritin knockout mice: A model of hyperferritinemia in the absence of iron overload. Blood 2001;98:525-32.
73. Deugnier Y, Moirand R, Guyader D, et al. Diagnostic d'une hyperferritinémie. Ann Biol Clin (Paris) 1998;56(Spec No):41-3.
74. Aguilar-Martinez P, Biron C, Masmejean C, et al. A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome. Blood 1996;88:1895.
75. Cremonesi L, Paroni R, Foglieni B, et al. Scanning mutations of the 5′UTR regulatory sequence of L-ferritin by denaturing high-performance liquid chromatography: Identification of new mutations. Br J Haematol 2003;121:173-9.
76. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776-81.
77. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004;32:131-8.
78. Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: A common mutation in hemochromatosis type 4. Blood 2002;100:733-4.
79. Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002;100:695-7.
80. Cazzola M, Cremonesi L, Papaioannou M, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002;119:539-46.
81. Barton JC, Acton RT, Rivers CA, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003;31:310-9.
82. Beutler E, Barton JC, Felitti VJ, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003;31:305-9.
83. Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003;31:299-304.
84. Gordeuk VR. African iron overload. Semin Hematol 2002;39:263-9.
85. Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc Natl Acas Sci USA 1995;92:2539-43.
86. Loréal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: New clinical, pathophysiological and therapeutic insights. J Hepatol 2002;36:851-56.
87. Mariani R, Arosio C, Pelucchi S, et al. Iron chelation therapy in aceruloplasminemia: Study of a patient with a novel missense mutation. Gut 2004;53:756-8.